CTOs on the Move

Integrated Medical Dlvry

www.imdelivery.com

 
Integrated Medical Dlvry LLC is a Oklahoma City, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Planned Parenthood Alhambra Health Center

Planned Parenthood Alhambra Health Center is a Alhambra, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pepid

Since 1994, PEPID has been a leading developer of clinical and drug information resources and mobile apps for healthcare providers, hospitals and schools. PEPIDs collection of clinical decision support resources help healthcare professionals become better clinicians and, most importantly, improves patient outcomes by aiding in diagnosis and management.

Enerhealth Botanicals

Improve, nourish and elevate with organic-certified mushroom coffee, vegan superfoods, herbal tinctures, cocoa, and other exceptional plant-based products.

Sava

Sava vets the vast world of cannabis and hand-picks the highest quality topicals, tinctures, vapes, edibles, oils, CBD, and flower for delivery in the SF Bay Area.

Foghorn Therapeutics

More than 20,000 genes make us human. Genes control critical aspects of health and disease — but what controls our genes? Foghorn® Therapeutics ($FHTX) is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic Control™ platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease. With Gene Traffic Control™ Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.